PetVivo's Leap: From Animal Health to a Dual-Market Biomedical Powerhouse

MINNEAPOLIS, MN – June 24, 2026 – PetVivo Holdings, a company that built its name on treating joint pain in horses and household pets, today announced a definitive pivot toward a far larger arena: human health. The emerging biomedical firm has entered into an agreement to acquire PiezoBioMembrane, Inc. (PBM), a developer of advanced functional biomaterials. The all-stock deal, valued at 3 million shares, is more than a simple acquisition; it's a declaration of intent to transform from a niche animal health provider into a diversified biomaterials platform with ambitions in regenerative medicine for both animals and humans.

The transaction will fold PBM into PetVivo’s subsidiary, Cosmeta Corp., creating a hub for next-generation biomaterials. "We believe this transaction represents a transformative step in PetVivo's long-term growth strategy," stated John Lai, CEO of PetVivo Holdings. By combining PBM's deep scientific innovation with PetVivo's commercialization and regulatory experience, the company is betting it can accelerate technologies that serve as a foundation for future medical breakthroughs.

A Strategic Pivot Under Financial Pressure

On the surface, this is a story of ambitious expansion. PetVivo has established a foothold in the veterinary market with products like SPRYNG®, an injectable that helps manage lameness in animals. However, a look at the company’s recent financial disclosures paints a more complex picture. While fiscal year 2025 saw revenues climb nearly 17% to $1.13 million, the company still posted a net loss of $8.40 million. More critically, a quarterly report filed earlier this year revealed a precarious liquidity situation, with cash reserves dwindling to just over $18,000.

Viewed through this lens, the acquisition of PBM appears less like a luxury and more like a strategic necessity. The move signals a calculated gamble to escape the confines of a lower-margin, capital-intensive device market and tap into a vastly more lucrative one. The all-stock nature of the deal, which includes milestone-based incentives for PBM’s shareholders, is a shrewd maneuver to conserve precious cash while pursuing transformative growth. This isn't an isolated move, either. It follows the company’s recent launch of PetVivo.ai, a software-as-a-service platform aimed at veterinarians, suggesting a broader strategy of diversification into higher-margin business models. By acquiring PBM, PetVivo is not just buying technology; it is buying a ticket to a much bigger game.

The Science Driving the Synergy

The core of this deal lies in PiezoBioMembrane's groundbreaking technology. The term "piezoelectric" refers to materials that generate an electric charge in response to mechanical stress. This property is not just an engineering concept; it’s fundamental to biology. Natural tissues like bone, cartilage, and even DNA exhibit piezoelectric properties, using these subtle electrical cues to guide growth and repair. PBM, a spin-off from the University of Connecticut, has harnessed this principle by developing a platform of biodegradable piezoelectric nanofibers.

These nanofibers can be formed into scaffolds that mimic the body's own healing mechanisms. When implanted and subjected to natural mechanical forces—like the movement of a joint during exercise—they generate a small electric current that stimulates and accelerates tissue regeneration. The potential was powerfully demonstrated in a preclinical study where a PBM scaffold implanted in a rabbit's knee led to the near-complete regeneration of both cartilage and bone.

This acquisition is the culmination of a pre-existing partnership. In 2025, the two companies signed a Master Services Agreement to explore combining PetVivo's protein-based biomaterial, used in its SPRYNG® product, with PBM’s piezoelectric nanofibers. The goal was to create a superior, biologically active material. This merger formalizes that synergy, bringing PBM's advanced science entirely in-house. "This transaction represents an exciting milestone for PBM and reflects the years of scientific development, innovation, and technology advancement undertaken by our team," said Thanh Nguyen, President of PiezoBioMembrane.

The IP Power Play and Market Opportunity

Beyond the science, this acquisition is a strategic intellectual property power play. PetVivo is gaining control over PBM’s entire platform, including a portfolio of patents, trade secrets, and proprietary formulations developed by its founders, who are prolific inventors in the field. This fortress of IP is crucial for defending a competitive position in the crowded and fast-moving regenerative medicine space.

And the market PetVivo is now targeting is immense. The global regenerative medicine market was valued at over $48 billion in 2025 and is projected by some analysts to explode to over $360 billion by 2034, fueled by an aging population and the rising prevalence of chronic diseases. Critically for PetVivo, the largest segment of this market is orthopedics—the very area where its SPRYNG® product has given it deep domain expertise. The global market for musculoskeletal regenerative medicine alone is expected to surpass $40 billion by 2030. When combined with the nearly $35 billion piezoelectric devices market, the scale of the opportunity comes into sharp focus, justifying the strategic risks involved.

Navigating the Path Forward: Regulation and Execution

The road ahead is promising but fraught with challenges. While PetVivo has experience navigating the FDA's Center for Veterinary Medicine (CVM), bringing a novel combination product to the human market is an entirely different undertaking. The regulatory pathway for regenerative medicine advanced therapies (RMATs) is complex and expensive, and the bar for approval is significantly higher.

However, the deal is structured to mitigate some of this risk. Tying a portion of the 3 million shares for PBM shareholders to the achievement of key development and regulatory milestones aligns the interests of both parties toward a successful outcome. It ensures that PBM’s key personnel remain invested in seeing the technology through the arduous journey to commercialization. As CEO John Lai noted, the combination of capabilities should "accelerate the advancement of technologies," while also opening doors to "grant funding, research collaborations, and research and development tax credit programs." This infusion of non-dilutive capital could prove vital for funding the long and costly R&D process. For PetVivo, this acquisition marks the beginning of a new chapter, one that will test its ability to execute on a far grander vision than its animal health origins ever suggested.